Despite insulin treatment and a meticulously controlled diet, approximately 15% of all patients with diabetes will, at some time, have non-healing wounds and this is the leading cause of lower extremity amputation. Wound healing involve cell adhesion, migration, proliferation, differentiation, and apoptosis. Abnormalities of distinct factors of wound healing like decreased growth factor production, angiogenic response, macrophage function, collagen accumulation, epidermal barrier function, and fibroblast migration and proliferation contribute to defective healing in diabetes. Relative or absolute lack of insulin or its action is a hallmark of diabetes disease and defective insulin action in the skin contributes to defects in wound healing [1]. Foot ulcers are common due to underlying angiopathy and neuropathy. Several therapeutic modalities like skin grafts, hydrocolloid dressings, and high-protein diets, but some may not be economically stable of associated with complication. Researches in past has shown that topical insulin accelerates wound healing in the skin of diabetic rats and humans [2]. Insulin stimulates the growth and development of different cell types and affects proliferation, migration, and secretion by keratinocytes, endothelial cells, and fibroblasts [3]. The purpose of this prospective, randomized study was to investigate the efficacy and safety of topical insulin in management of patients with chronic diabetic foot ulcers.